Matrix Metalloproteinases 2 and 9 Polymorphism in Patients With Myeloproliferative Diseases A STROBE-Compliant Observational Study

Basit Öğe Kaydı
dc.authoridUCTEPE, EYYUP/0000-0002-1820-9094|MARAL, SENEM/0000-0003-4766-1861|Kosar, Ali/0000-0001-6283-6717|Yildirim, Derya/0000-0003-2771-7725|acar, muradiye/0000-0003-4357-5229;
dc.contributor.authorMaral, Senem
dc.contributor.authorAcar, Muradiye
dc.contributor.authorBalcik, Ozlem Sahin
dc.contributor.authorUctepe, Eyyup
dc.contributor.authorHatipoglu, Omer Faruk
dc.contributor.authorAkdeniz, Derya
dc.contributor.authorAltun, Hatice Uludag
dc.date.accessioned2025-10-24T18:09:21Z
dc.date.available2025-10-24T18:09:21Z
dc.date.issued2015
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractChronic myeloproliferative disorders such as polycythemia vera (PV), essential thrombocytosis (ET), and idiopathic myelofibrosis arise from clonal proliferation of neoplastic stem cells in the bone marrow. Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that have potential to degrade all types of extracellular matrix (ECM) and also play a role in remodeling of the ECM. It is known that MMPs play a role in bone marrow remodeling. The primary goal of our study is to explore the relationship between chronic myeloproliferative diseases and some of MMP gene polymorphisms. The demonstration of a relationship will help to understand whether these polymorphisms may be a potential early diagnosis marker of the diseases. Patients were selected from outpatient clinks of Turgut Ozal University Hospital, Ankara, Turkey, between December 2010 and May 2011. Twenty-eight patients that previously diagnosed and followed-up with PV, 17 with secondary polycythemia (SP), and 12 with ET were enrolled in the study, along with a control group of 22 healthy people. DNA was isolated from peripheral blood. Using polymerase chain reaction restriction fragment length polymorphism method, MMP2 and MMP9 gene polymorphisms were analyzed with agarose gel electrophoresis. There was a statistically significant difference between the study groups and the control group in terms of Gin279Arg polymoiphisms rates of MMP9. The highest MMP9 Gln279Arg polymorphism rate was observed in the ET group. But nobody from the control group had polymorphic MMP9. There was no statistically significant difference between the groups in terms of MMP2-735 C > T polymorphism rates. In conclusion, MMP9 gene Gln279Arg polymorphism was associated with ET, SP, and PV diseases. Hence, we believe that these gene polymorphisms may play a role in the mechanism of bone marrow fibrosis and may be a factor that increases the risk of thrombosis. Illumination of the molecular basis of the relationship between MMP-thrombosis and MMP-librosis provides a better understanding of the pathophysiology of PV and ET diseases mid will allow new approaches to diagnosis and treatment.
dc.identifier.doi10.1097/MD.0000000000000732
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue16
dc.identifier.pmid25906101
dc.identifier.scopus2-s2.0-84929658501
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000000732
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3577
dc.identifier.volume94
dc.identifier.wosWOS:000353794700012
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofMedicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectFibronectin-Like Domain; Iv Collagenase; Tissue Inhibitors; Functional Polymorphisms; Collagenolytic Activity; Genetic Polymorphisms; Gelatinase-A; Mmp-2 Levels; Mr 72,000; Risk
dc.titleMatrix Metalloproteinases 2 and 9 Polymorphism in Patients With Myeloproliferative Diseases A STROBE-Compliant Observational Study
dc.title.alternativeMatrix metalloproteinases 2 and 9 polymorphism in patients with myeloproliferative diseases: A STROBE-compliant observational study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu